Connor, Clark & Lunn Investment Management (CC&L)’s Pliant Therapeutics PLRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$611K	Buy	536,081 +18,628	+4%	+$22.7K	﹤0.01%	1330
2026 Q1	$652K	Buy	517,453 +145,502	+39%	+$184K	﹤0.01%	1260
2025 Q4	$454K	Buy	371,951 +347,611	+1,428%	+$522K	﹤0.01%	1324
2025 Q3	$36K	Buy	+24,340	New	+$37.1K	﹤0.01%	1471
2024 Q4	–	Sell	-34,611	Closed	-$388K	–	1589
2024 Q3	$388K	Buy	+34,611	New	+$433K	﹤0.01%	1160
2023 Q2	–	Sell	-43,479	Closed	-$1.16M	–	1454
2023 Q1	$1.16M	Buy	+43,479	New	+$1.24M	0.01%	677

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PLRX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Pliant Therapeutics (PLRX) stake by 3.6% in Q2 2026, buying an estimated $22.7K and bringing the position to 536,081 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #1330.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PLRX in Q1 2023 and has held it in 6 quarters since. The position peaked at $1.16M in Q1 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 536,081 shares of Pliant Therapeutics worth $611K as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 18,628 Pliant Therapeutics shares in Q2 2026, an estimated $22.7K.
Pliant Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1330 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Pliant Therapeutics in Q1 2023 and has held it in 6 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Pliant Therapeutics position peaked at $1.16M in Q1 2023.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.